Erasca, Inc.
corporate_fare Company Profile
Erasca, Inc. (NASDAQ:ERAS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for ERAS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ERAS spans 8-K, 10-Q, 424B5.
Recent high-impact activity:
- Erasca Pulls Forward Phase 3 Pancreatic Trial to 1H 2027 After 44% ORR Data
- Erasca's ERAS-0015 Posts 44% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027
- Pan-RAS Glue Hits 69% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027
- Erasca Lands BMS Collaboration to Test ERAS-0015 With Navlimetostat in Pancreatic Cancer
- Erasca Q3 Loss Widens to $51.3M; $947.8M Cash Funds Pipeline Into 2027
Financial Snapshot
Short Interest & Short Volume
8.89 days to coverFINRA reported short interest of 37,156,627 shares in ERAS as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 8.9 days to cover at its recent average daily volume. On November 20, 2026, 54.7% of ERAS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ERAS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-14.
Follow-On Offering Priced at $17.50 · Net Proceeds and Use of Funds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →